



IPSEN 2014 KEY FIGURES

- Main products: **Decapeptyl®**, **Somatuline®**, **Dysport®**, **Hexvix®**, **Smecta®**, **Tanakan®**, **Forlax®**
- Direct commercial presence in **40** countries
- Drugs marketed in **115** countries
- Sales balanced across **four** franchises
- Sales > **€1.2 billion**
- **R&D** expenditure €260 million, **21%** of Group sales
- **4,600** employees

2014 SALES BY GEOGRAPHIC AREA



2014 SALES BY FRANCHISE



IPSEN - OUR VISION

Improving the lives of **patients** is what drives us. The search for **innovative** solutions to disabling conditions is at the heart of everything we do. Increased life expectancy is making the **pursuit** of our **inspiring** vocation more vital than ever. Finding effective therapeutic solutions to **cure disease**, relieve suffering and bring **value** to the community.

IPSEN - Innovation For Patient Care Through Partnering



Christophe Jean,
EVP, Corporate
Strategy and
Business
Development

What we are looking for:

- Opportunities to leverage our commercial platform by obtaining marketing rights for products in our therapeutic focus areas.
 - On-market or late-stage product opportunities synergistic with our US commercial footprint focused in the areas of oncology, endocrinology and neurology
- Partnerships to develop novel medicines in our franchise focus ie endocrinology, neurology, uro-oncology and primary care focused on gastroenterology.
- Enabling technologies, complementary resources or skills for discovery and development programs:
 - Novel and early-stage technology platforms,
 - New indications, diagnostics, delivery formulation or device technologies,
 - Knowledge that advances the understanding of peptides and toxins.

OUR PLATFORMS PEPTIDES & TOXINS

OUR THERAPEUTIC AREAS ENDOCRINOLOGY NEUROLOGY URO-ONCOLOGY PRIMARY CARE (GI)

OTHER STRATEGIC FOCUS AREAS EARLY-STAGE R&D DELIVERY & DEVICES MANUFACTURING OUR GLOBAL FOOTPRINT



(L to R): Judith Hills, SVP CBD judith.hills@ipsen.com
 Sonia Benhamida, Oncology CBD sonia.benhamida@ipsen.com
 Peter Berry, Scientific Affairs peter.berry@ipsen.com
 Jonathan Chriqui, Primary Care, Manufacturing jonathan.chriqui@ipsen.com
 Scott Cuthill, Endocrinology, Regional CBD scott.cuthill@ipsen.com
 Wendy Dwyer, US and Neurology CBD wendy.dwyer@ipsen.com
 Elena Ritsou, Early Stage R&D, BD elena.ritsou@ipsen.com

Each team member has diverse related experience beyond business development that allows them to quickly understand the value of your asset and move it through our defined process.

> 30 active
partnerships

www.ipsen.com